Search | Page 7 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management

    ... and iron chelation. MANAGEMENT OF PROGRESSIVE OR REFRACTORY DISEASE: At the present time, there are no approved interventions for patients with progressive or refractory disease particularly after hypomethylating based therapy. Options ...

    Research Article last updated 07/20/2018 - 5:14pm.

  2. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management

    ... and iron chelation. Management of progressive or refractory disease: At the present time there are no approved interventions for patients with progressive or refractory disease particularly after hypomethylating based therapy. Options ...

    Research Article last updated 07/20/2018 - 5:14pm.

  3. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management

    ... and iron chelation. Management of progressive or refractory disease: There are no approved interventions for patients with progressive or refractory disease particularly after hypomethylating based therapy. Options ...

    Research Article last updated 07/20/2018 - 5:15pm.

  4. Anemia as the Main Manifestation of Myelodysplastic Syndromes

    ... Several new agents are under evaluation for ESA refractory /relapsed MDS patients, targeting different putative mechanisms ...

    Research Article last updated 07/20/2018 - 5:15pm.

  5. Myelodysplastic syndromes.

    ... are classified as having 1 of 5 subtypes of disease: refractory anemia (RA); RA with ringed sideroblasts (RARS); RA ...

    Research Article last updated 07/20/2018 - 5:14pm.

  6. Reduced intensity conditioning and co-transplantation of unrelated peripheral stem cells combined with umbilical cord mesenchymal stem/stroma cells for young patients with refractory severe aplastic anemia.

    Journal Title:  Int J Hematol Primary Author:  Fu Y Author(s):  Fu Y, Wang Q,...

    Research Article last updated 07/20/2018 - 5:15pm.

  7. Immunosuppressive Therapy

    ... the U.S. Food and Drug Administration in 2014 to treat refractory aplastic anemia . In 2018, Eltrombopag was FDA approved ...

    Topic section last updated 07/06/2018 - 11:17am.

  8. Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Achieved Outcomes Comparable With Matched Unrelated Donor Transplantation in Young Acquired Severe Aplastic Anemia

    ... patients MUDs for HSCT. Most were heavily transfused and refractory to previous immunotherapy. The median durations for myeloid ...

    Research Article last updated 06/13/2018 - 2:28pm.

  9. A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients with Myelodysplastic Syndrome (MDS)

    ... cell transplantation. For patients in the relapse or refractory cohort, any other therapy not being a hypomethylating agent ...

    Clinical Trial last updated 05/14/2018 - 1:57pm.

  10. Patient Trusts Her Instincts in Finding the Right Treatment

    ... MDS (myelodysplastic syndrome). Specifically, it was the Refractory Anemia with Ringed Sideroblasts, (RARS) subtype.  I was ...

    Patient Chronicle last updated 05/10/2018 - 11:01am.